PFE vs SENS

Pfizer Inc. remains a mature, large-cap pharmaceutical company with its market capitalization slightly declining to $154.21B. While the company pursues strategic initiatives like cost savings and continues pipeline development (Lyme vaccine, mRNA flu/COVID combo), these efforts are primarily aimed at stabilizing revenue and profitability against significant headwinds, not generating 10x growth. Th...

Senseonics (SENS) continues to present an extremely high-risk, high-reward profile with the path to 10x potential remaining significantly challenging. While the Eversense long-term implantable CGM offers a unique proposition in the vast diabetes market, previous commercialization struggles and persistent cash burn are still critical concerns. The market cap has slightly adjusted from the previous ...